Lilly Limerick: Expanding Ireland’s role in Global Medicine Manufacturing

Eli Lilly and Company’s most recent investment in Ireland, it's Limerick manufacturing facility, represents one of the most significant life sciences developments in the region in recent years.

Yet those involved in its development say that the project is about more than scale. It forms part of a broader global expansion by Lilly to increase manufacturing capacity and accelerate the delivery of medicines to patients worldwide.

Ireland has long been central to Lilly’s international operations. The company established its first Irish presence in Kinsale in 1978, and over the decades has steadily grown its footprint across the country.

The Limerick site adds to that history, reinforcing Ireland’s position as a key hub within Lilly’s global manufacturing network.

Few people have been closer to the development of the Limerick facility than Dave Riordan, who leads the site and has been involved in the project since its early planning stages.

Michael Lohan, CEO IDA; Dave Ricks, CEO Eli Lilly and Company; Peter Burke, Minister for Enterprise Trade & Employment and Dave Riordan, vice president, Lilly Limerick site head pictured at the announcement of the company's $1 billion expansion of its Limerick manufacturing site in 2024

For him, the project represents an opportunity to rethink how modern manufacturing sites operate at a time when demand for innovative medicines is increasing and technology is transforming the way those medicines are produced.

“Speed to patient has always been central to what we do at Lilly.” Riordan says “It is our responsibility to constantly learn and improve. In fact, the legacy we leave behind is built on one simple belief — take what you find here and make it better.

“In Limerick we have a team of highly skilled and talented people that will support the reliable production of medicines for patients around the world.”

Central to the site’s design is a digital-first approach to manufacturing. Advanced automation, integrated data systems, and real-time monitoring are woven into how the facility operates.

Across the biopharmaceutical sector, these capabilities are becoming increasingly important, helping to reduce variability in production, improve quality oversight, and streamline processes that can ultimately shorten the time it takes to bring medicines to patients.

Sustainability has been equally a defining feature of the plant. Earlier this year, it became the first Lilly facility worldwide to achieve LEED Gold certification, a milestone that places it among a growing number of buildings designed to meet rigorous environmental standards.

Energy performance, resource efficiency, and long-term operational resilience were built into the design from the ground up, reflecting our commitment to balance increased production with environmental responsibility.

The site is also committed to strengthen the regional talent pipeline. Through partnerships with the University of Limerick and programmes such as the emerging iBio programme, Lilly is supporting initiatives aimed at developing future talents in science, engineering and manufacturing.

These collaborations are designed to help ensure that the specialised skills required for highly automated, highly regulated manufacturing environments continue to grow alongside the industry itself.

Taken together, these elements reflect how the Limerick facility fits into Lilly’s broader strategy: not just an expansion of global manufacturing capacity, but a long-term investment in Ireland — in its people, its communities, and its future.

For Lilly, it is the latest expression of a belief that has guided the company's presence on this island for forty-five years, “Take what you find here, and make it better and better, and never stop looking for answers for patients who need them”.

For Limerick, and more broadly, Ireland, the project reinforces the country’s role in an industry that continues to grow in both economic importance and global health impact.

*Sponsored Content